Background Penetrance of breast cancer (BC) among women who carry pathogenic variants (PVs) in BRCA1 is incomplete, and the ...
Findings may support development of more refined personalized breast cancer risk prediction models for BRCA1 pathogenic variant carriers.
The 23andMe Research Institute said that some people lose less than 5% with GLP-1 drugs, while others can lose 20% or more, ...
In a recent study published in Nature Genetics, a group of researchers advanced variant effect prediction across the human proteome by integrating deep evolutionary signals with human population ...
Spread the loveThe quest for effective weight-loss solutions has led to a surge in popularity for medications like Ozempic, Mounjaro, and Zepbound. These GLP-1 receptor agonists have shown promising ...
Genetic risk models, including PREMMplus and BOADICEA/CanRisk, refine breast cancer risk assessment by incorporating genetic status and polygenic risk scores. Challenges in classifying gene variants, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results